The rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which have historically been reserved for later lines of therapy, are being used earlier in treatment, placing additional pressure on the already-limited gram-negative infection (GNI) armamentarium. Despite the launch of antibiotics, such as Avycaz / Zavicefta, Zerbaxa, Vabomere, Xerava, and Zemdri, unmet need remains for additional effective treatments. Although the recent launches of Recarbrio and Fetroja will partially address this unmet need, commercial opportunities still exist for emerging therapies with efficacy in patients with drug-resistant infections, especially those infections that are associated with high rates of mortality. However, the market is heavily genericized, and cost-containment measures may limit commercial success.
- What are the drivers and constraints in the hospital-treated (HT)-GNI therapy market, and how will the market evolve over the forecast period? How will rising antibiotic resistance rates and the entry of new generics shape the market?
- How large are the different GNI indications? What are the resistance rates to different classes of antibiotics across several pathogen species?
- How will different emerging therapies address current unmet needs? What emerging therapies do infectious disease specialists consider most promising, and where will these therapies be used?
- On what attributes will emerging therapies need to improve to compete with currently marketed products? What challenges will they face?
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan
Primary Research: More than 20 country-specific interviews with thought-leading infectious disease specialists supported by survey data collected for this and other DRG research.
Epidemiology: Diagnosed events of GNIs segmented by key indications (nosocomial pneumonia, complicated skin and skin structure infections / surgical site infections, bloodstream infections, complicated intra-abdominal infections, urinary tract infections), pathogens (E.coli, Pseudomonas, Acinetobacter, Klebsiella), resistance, and country.
FORECAST: Ten-year, annualized, drug-level sales and patient share of key GNI therapies through 2029, segmented by brands / generics, geography, and five key indications.
Emerging Therapies: Phase III/PR: 7 drugs; Phase I/Phase II: 15 drugs; coverage of select preclinical products
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary market research.